7 March 2024 in BJOG: An International Journal of Obstetrics & Gynaecology
3 April 2024 in International Journal of Gynecology & Obstetrics
1 July 2022 in Ain Shams Journal of Forensic Medicine and Clinical Toxicology
Background: Synthetic cannabinoids are currently the largest group of new psychoactive substances. Those that have been subjected to legal control are replaced by newer uncontrolled substances, which cause constant and dynamic changes to the drug market. AMB-FUBINACA is one of the recent synthetic cannabinoids appeared globally. In 2018, the official spokesman for the Ministry of Health in Egypt announced that the Strox consists of five types of synthetic cannabinoids which have been added to the Egyptian list of highly addictive and dangerous narcotics. These SCs are; AB-FUBINACA, AMB-FUBINACA, 5F-ADB, AB-CHMINACA, and XLR-11. Aim of the work: To spotlight the toxic effect of AMB-FUBINACA as a new synthetic cannabinoid. Conclusion: AMB-FUBINACA has been the focus of interest by health care professionals, as their use put the health of many humans at risk especially young adults. Received in original form: 24 December 2021 Accepted in a final form: 30 June 2022
1 July 2022 in Ain Shams Journal of Forensic Medicine and Clinical Toxicology
Background: AMB-FUBINACA abuse was confirmed in case reports of a mass intoxication in the United States. Also it was reported that in New Zealand, there were at least 20 deaths related to the use of MMB-FUBINACA. Aim of the Work: To detect the toxic effect of synthetic cannabinoid (AMB-FUBINACA) with different doses on the testis of adult male albino rats histopathologically and Biochemically. Methods: the present work was conducted on 40 sexually mature male albino rats. Rats were divided into 5 groups 8 rats each as follow Group I: Negative control group, Group II: Positive control group where animals received ethanol 5%, Group III: Rats treated with AMB-FUBINACA at dose of 2.5 mg/kg dissolved in ethanol 5%, Group IV: Rats treated with AMB-FUBINACA at dose of 5 mg/kg dissolved in ethanol 5% and Group V: Rats treated with AMB-FUBINACA at dose of 10 mg/kg dissolved in ethanol 5% given by intraperitoneal injection for 4 weeks. Results: a significant decrease of testosterone level in AMB-FUBINACA treated groups compared to the control groups and degenerative changes in seminiferous tubules was also observed in treated groups. Conclusion: administration of AMB-FUBINACA for 4weeks was associated with toxic effects in testis